A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Atazanavir; Cobicistat; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms Study 109
- Sponsors Gilead Sciences
- 16 Apr 2020 Status changed from active, no longer recruiting to completed.
- 12 Mar 2020 Planned End Date changed from 1 Dec 2019 to 1 Apr 2020.
- 24 Sep 2019 This trial has been completed in Portugal.